Here we review how biomarkers have been used in the design, execution and interpretation of recent clinical studies of therapeutic candidates targeting cytokine-mediated inflammatory pathways in asthma. This review focuses on type 2 inflammation, as there are multiple therapeutics and/or clinical studies that can be compared within that specific pathway. Comparative analyses of data from these clinical studies illustrate the utility of biomarkers to quantify pharmacodynamic effects, clarify mechanism of action and stratify patients, which may facilitate the interpretation of outcomes in the development of molecularly targeted therapies. These case examples provide a basis for biomarker considerations in the design of future studies in the asthma setting.
Keywords: AMG 317; FeNO; GSK679586; asthma; benralizumab; biomarkers; brodalumab; dupilumab; eosinophils; golilumab; lebrikizumab; mepolizumab; omalizumab; patient selection; periostin; pharmacodynamics; reslizumab; tralokinumab.